Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
Clinical trial NCT04560166 · TERMINATED
Trial details
- NCT number
- NCT04560166
- Sponsor
- Y-mAbs Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-08
- Primary completion
- 2022-09-21
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.